Low-dose tamoxifen and raloxifene enhance therapeutic effect of ribitol in mouse model of FKRP mutation-related muscular dystrophy
Main Article Content
Abstract
Tamoxifen and raloxifene are selective estrogen receptor modulators (SERM) used to treat or reduce the risk of breast cancer as well as for osteoporosis. These drugs act to block estrogen in various tissues while having a pro-estrogen activity in others. Furthermore, they have been shown to have anti-fibrotic and anti-inflammatory properties making them a potential therapeutic option for muscular dystrophy. Previous studies by our lab and others have examined tamoxifen and raloxifene treatments in muscular dystrophy mouse models with success. These include numerous studies in the mdx mouse resulting in improved muscle function and pathology. Studies in our lab demonstrated long-term, dose dependent improvements in muscle function and pathology with daily treatment of up to 50 mg/kg tamoxifen and up to 100 mg/kg raloxifene. Additionally, ribitol has been shown to be effective in mitigating the dystrophic pathology in the FKRP-P448Lneo- mutant mouse, thus providing a potential supplement option for improving the effectiveness of current drugs. Here we examined the effectiveness of low-dose tamoxifen and raloxifene with and without ribitol supplement. FKRP-P448Lneo- mutant mice were treated with 1 mg/kg tamoxifen or 10 mg/kg raloxifene with and without 2 g/kg ribitol daily for 12 months. Muscle function was examined using grip force, treadmill, whole body plethysmography and echocardiogram at 6 and 12 months. Muscle histology and pathology was examined at 12 months. Muscle function improvements, specifically in treadmill distance and grip force, were seen after 6 months of treatment with combined treatment showing further improvement over each drug alone. Improvements were also noted in respiratory and cardiac parameters. Although there was a reduction in improvements after 12 months of treatment the treated animals retained higher function over untreated controls. Furthermore, an increase in alpha-dystroglycan glycosylation was noted in the combination treated groups as well as improvements in fibrosis and central nucleation in all treated groups but more prominent with the combined treatment. Taken together these data suggest the combinatorial treatment is effective over drug alone. These results demonstrate the potential benefit of low dose tamoxifen and raloxifene for the treatment of FKRP-related muscular dystrophies and other muscular dystrophies.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Mendell JR, Rodino-Klapac LR, Rosales XQ, et al. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Ann Neurol. Nov 2010;68(5):629-38. doi:10.1002/ana.22251
3. Qiao C, Wang CH, Zhao C, et al. Muscle and heart function restoration in a limb girdle muscular dystrophy 2I (LGMD2I) mouse model by systemic FKRP gene delivery. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't. Mol Ther. Nov 2014;22(11):1890-9. doi:10.1038/mt.2014.141
4. Vannoy CH, Leroy V, Lu QL. Dose-Dependent Effects of FKRP Gene-Replacement Therapy on Functional Rescue and Longevity in Dystrophic Mice. Mol Ther Methods Clin Dev. Dec 14 2018;11:106-120. doi:10.1016/j.omtm.2018.10.004
5. Vannoy CH, Xu L, Keramaris E, Lu P, Xiao X, Lu QL. Adeno-associated virus-mediated overexpression of LARGE rescues alpha-dystroglycan function in dystrophic mice with mutations in the fukutin-related protein. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't. Hum Gene Ther Methods. Jun 2014;25(3):187-96. doi:10.1089/hgtb.2013.151
6. Wu B, Drains M, Shah SN, et al. Ribitol dose-dependently enhances matriglycan expression and improves muscle function with prolonged life span in limb girdle muscular dystrophy 2I mouse model. PLoS One. 2022;17(12):e0278482. doi:10.1371/journal.pone.0278482
7. Wu B, Shah SN, Lu P, et al. Long-Term Treatment of Tamoxifen and Raloxifene Alleviates Dystrophic Phenotype and Enhances Muscle Functions of FKRP Dystroglycanopathy. Am J Pathol. Apr 2018;188(4):1069-1080. doi:10.1016/j.ajpath.2017.12.011
8. Wu B, Shah SN, Lu P, et al. Glucocorticoid Steroid and Alendronate Treatment Alleviates Dystrophic Phenotype with Enhanced Functional Glycosylation of alpha-Dystroglycan in Mouse Model of Limb-Girdle Muscular Dystrophy with FKRPP448L Mutation. Am J Pathol. Jun 2016;186(6):1635-48. doi:10.1016/j.ajpath.2016.02.015
9. Cataldi MP, Blaeser A, Lu P, Leroy V, Lu QL. ISPD Overexpression Enhances Ribitol-Induced Glycosylation of alpha-Dystroglycan in Dystrophic FKRP Mutant Mice. Mol Ther Methods Clin Dev. Jun 12 2020;17:271-280. doi:10.1016/j.omtm.2019.12.005
10. Cataldi MP, Lu P, Blaeser A, Lu QL. Ribitol restores functionally glycosylated alpha-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice. Nat Commun. Aug 27 2018;9(1):3448. doi:10.1038/s41467-018-05990-z
11. Gerin I, Ury B, Breloy I, et al. ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol phosphate onto alpha-dystroglycan. Nat Commun. May 19 2016;7:11534. doi:10.1038/ncomms11534
12. Kanagawa M, Kobayashi K, Tajiri M, et al. Identification of a Post-translational Modification with Ribitol-Phosphate and Its Defect in Muscular Dystrophy. Cell Rep. Mar 8 2016;14(9):2209-23. doi:10.1016/j.celrep.2016.02.017
13. Cataldi MP, Vannoy CH, Blaeser A, et al. Improved efficacy of FKRP AAV gene therapy by combination with ribitol treatment for LGMD2I. Mol Ther. Dec 6 2023;31(12):3478-3489. doi:10.1016/j.ymthe.2023.10.022
14. Rosenberg AS, Puig M, Nagaraju K, et al. Immune-mediated pathology in Duchenne muscular dystrophy. Sci Transl Med. Aug 5 2015;7(299):299rv4. doi:10.1126/scitranslmed.aaa7322
15. Quattrocelli M, Zelikovich AS, Salamone IM, Fischer JA, McNally EM. Mechanisms and Clinical Applications of Glucocorticoid Steroids in Muscular Dystrophy. J Neuromuscul Dis. 2021;8(1):39-52. doi:10.3233/JND-200556
16. Dorchies OM, Reutenauer-Patte J, Dahmane E, et al. The anticancer drug tamoxifen counteracts the pathology in a mouse model of duchenne muscular dystrophy. Am J Pathol. Feb 2013;182(2):485-504. doi:10.1016/j.ajpath.2012.10.018
17. Gayi E, Neff LA, Massana Munoz X, et al. Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy. Nat Commun. Nov 19 2018;9(1):4848. doi:10.1038/s41467-018-07058-4
18. Awano H, Blaeser A, Keramaris E, et al. Restoration of Functional Glycosylation of alpha-Dystroglycan in FKRP Mutant Mice Is Associated with Muscle Regeneration. Am J Pathol. Jul 2015;185(7):2025-37. doi:10.1016/j.ajpath.2015.03.017
19. Blaeser A, Awano H, Wu B, Lu QL. Progressive Dystrophic Pathology in Diaphragm and Impairment of Cardiac Function in FKRP P448L Mutant Mice. PLoS One. 2016;11(10):e0164187. doi:10.1371/journal.pone.0164187
20. Botti V, Menzel O, Staedler D. A state-of-the-art review of tamoxifen as a potential therapeutic for duchenne muscular dystrophy. Front Pharmacol. 2022;13:1030785. doi:10.3389/fphar.2022.1030785
21. Henzi BC, Schmidt S, Nagy S, et al. Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. Oct 2023;22(10):890-899. doi:10.1016/S1474-4422(23)00285-5
22. Birnbaum F, Eguchi A, Pardon G, Chang ACY, Blau HM. Tamoxifen treatment ameliorates contractile dysfunction of Duchenne muscular dystrophy stem cell-derived cardiomyocytes on bioengineered substrates. NPJ Regen Med. Mar 18 2022;7(1):19. doi:10.1038/s41536-022-00214-x
23. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. Jun 21 2006;295(23):2727-41. doi:10.1001/jama.295.23.joc60074
24. DeMichele A, Troxel AB, Berlin JA, et al. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. J Clin Oncol. Sep 1 2008;26(25):4151-9. doi:10.1200/JCO.2007.14.0921
25. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. Aug 2004;89(8):3841-6. doi:10.1210/jc.2003-032058
26. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. Dec 4 1997;337(23):1641-7. doi:10.1056/NEJM199712043372301
27. Hoyt JA, Fisher LF, Buelke-Sam JL, Francis PC. The selective estrogen receptor modulator, raloxifene: reproductive assessments following premating exposure in female rats. Reprod Toxicol. May-Jun 1998;12(3):233-45. doi:10.1016/s0890-6238(98)00005-7
28. Murakami Y, Fukasawa M, Kaneko Y, Suzuki T, Wakita T, Fukazawa H. Selective estrogen receptor modulators inhibit hepatitis C virus infection at multiple steps of the virus life cycle. Microbes Infect. Jan 2013;15(1):45-55. doi:10.1016/j.micinf.2012.10.003
29. Montoya MC, Krysan DJ. Repurposing Estrogen Receptor Antagonists for the Treatment of Infectious Disease. mBio. Dec 18 2018;9(6) doi:10.1128/mBio.02272-18
30. Peretz J, Pekosz A, Lane AP, Klein SL. Estrogenic compounds reduce influenza A virus replication in primary human nasal epithelial cells derived from female, but not male, donors. Am J Physiol Lung Cell Mol Physiol. Mar 1 2016;310(5):L415-25. doi:10.1152/ajplung.00398.2015
31. Takeda M, Ikeda M, Mori K, et al. Raloxifene inhibits hepatitis C virus infection and replication. FEBS Open Bio. 2012;2:279-83. doi:10.1016/j.fob.2012.08.003
32. Weickert TW, Weinberg D, Lenroot R, et al. Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol Psychiatry. Jun 2015;20(6):685-94. doi:10.1038/mp.2015.11
33. Chan YM, Keramaris-Vrantsis E, Lidov HG, et al. Fukutin-related protein is essential for mouse muscle, brain and eye development and mutation recapitulates the wide clinical spectrums of dystroglycanopathies. Hum Mol Genet. Oct 15 2010;19(20):3995-4006. doi:ddq314 [pii] 10.1093/hmg/ddq314